FBIO PE Ratio & Valuation,Is FBIO Overvalued

FBIO Relative Valuation

FBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FBIO is overvalued; if below, it's undervalued.

Historical Valuation

Fortress Biotech Inc (FBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.92 is considered Fairly compared with the five-year average of -3.48. The fair price of Fortress Biotech Inc (FBIO) is between 2.67 to 9.71 according to relative valuation methord.

Relative Value

Fair Zone

2.67-9.71

Current Price：2.93

Fair

-1.82

-0.73

EV/EBITDA

Fortress Biotech Inc. (FBIO) has a current EV/EBITDA of -0.73. The 5-year average EV/EBITDA is -0.70. The thresholds are as follows: Strongly Undervalued below -2.55, Undervalued between -2.55 and -1.63, Fairly Valued between 0.22 and -1.63, Overvalued between 0.22 and 1.14, and Strongly Overvalued above 1.14. The current Forward EV/EBITDA of -0.73 falls within the Historic Trend Line -Fairly Valued range.

-1.22

EV/EBIT

Fortress Biotech Inc. (FBIO) has a current EV/EBIT of -1.22. The 5-year average EV/EBIT is -0.79. The thresholds are as follows: Strongly Undervalued below -2.66, Undervalued between -2.66 and -1.72, Fairly Valued between 0.15 and -1.72, Overvalued between 0.15 and 1.08, and Strongly Overvalued above 1.08. The current Forward EV/EBIT of -1.22 falls within the Historic Trend Line -Fairly Valued range.

0.92

Fortress Biotech Inc. (FBIO) has a current PS of 0.92. The 5-year average PS is 1.44. The thresholds are as follows: Strongly Undervalued below -1.32, Undervalued between -1.32 and 0.06, Fairly Valued between 2.82 and 0.06, Overvalued between 2.82 and 4.21, and Strongly Overvalued above 4.21. The current Forward PS of 0.92 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Fortress Biotech Inc. (FBIO) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.35. The thresholds are as follows: Strongly Undervalued below -5.75, Undervalued between -5.75 and -3.55, Fairly Valued between 0.84 and -3.55, Overvalued between 0.84 and 3.04, and Strongly Overvalued above 3.04. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Fortress Biotech Inc. (FBIO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.04. The thresholds are as follows: Strongly Undervalued below -0.30, Undervalued between -0.30 and -0.17, Fairly Valued between 0.08 and -0.17, Overvalued between 0.08 and 0.21, and Strongly Overvalued above 0.21. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Fortress Biotech Inc (FBIO) has a current Price-to-Book (P/B) ratio of 1.63. Compared to its 3-year average P/B ratio of 2.04 , the current P/B ratio is approximately -20.27% higher. Relative to its 5-year average P/B ratio of 2.19, the current P/B ratio is about -25.48% higher. Fortress Biotech Inc (FBIO) has a Forward Free Cash Flow (FCF) yield of approximately -72.73%. Compared to its 3-year average FCF yield of -242.15%, the current FCF yield is approximately -69.97% lower. Relative to its 5-year average FCF yield of -177.57% , the current FCF yield is about -59.04% lower.

1.63

P/B

Median3y

2.04

Median5y

2.19

-72.73

FCF Yield

Median3y

-242.15

Median5y

-177.57

Competitors Valuation Multiple

The average P/S ratio for FBIO's competitors is 5.01, providing a benchmark for relative valuation. Fortress Biotech Inc Corp (FBIO) exhibits a P/S ratio of 0.92, which is -81.61% above the industry average. Given its robust revenue growth of 20.52%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of FBIO increased by 44.69% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.86 to -14.75.

The secondary factor is the Revenue Growth, contributed 20.52%to the performance.

Overall, the performance of FBIO in the past 1 year is driven by P/E Change. Which is more unsustainable.

20.52%

14.63M → 17.63M

Revenue Growth

-127.44%

-182.47 → 50.07

Margin Expansion

151.61%

-5.86 → -14.75

P/E Change

44.69%

2.03 → 2.93

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Fortress Biotech Inc (FBIO) currently overvalued or undervalued?

What is Fortress Biotech Inc (FBIO) fair value?

FBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Fortress Biotech Inc (FBIO) is between 2.67 to 9.71 according to relative valuation methord.

How does FBIO's valuation metrics compare to the industry average?

What is the current P/B ratio for Fortress Biotech Inc (FBIO) as of Dec 15 2025?

As of Dec 15 2025, Fortress Biotech Inc (FBIO) has a P/B ratio of 1.63. This indicates that the market values FBIO at 1.63 times its book value.

What is the current FCF Yield for Fortress Biotech Inc (FBIO) as of Dec 15 2025?

As of Dec 15 2025, Fortress Biotech Inc (FBIO) has a FCF Yield of -72.73%. This means that for every dollar of Fortress Biotech Inc’s market capitalization, the company generates -72.73 cents in free cash flow.

What is the current Forward P/E ratio for Fortress Biotech Inc (FBIO) as of Dec 15 2025?

As of Dec 15 2025, Fortress Biotech Inc (FBIO) has a Forward P/E ratio of -1.82. This means the market is willing to pay $-1.82 for every dollar of Fortress Biotech Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Fortress Biotech Inc (FBIO) as of Dec 15 2025?

As of Dec 15 2025, Fortress Biotech Inc (FBIO) has a Forward P/S ratio of 0.92. This means the market is valuing FBIO at $0.92 for every dollar of expected revenue over the next 12 months.

FBIO Valuation